Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
A Prospective, Randomized, Phase II, Multicenter Clinical Study of Serplulimab Combined with First-Line Targeted Therapy and Chemotherapy with or Without Radiation in the First-Line Treatment of Advanced Colorectal Cancer
Sponsor: Fudan University
A PHASE2 clinical study on Advanced Colorectal Carcinoma and Immunotherapy, this trial is actively recruiting participants. The trial is conducted by Fudan University and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .